Filing Flows › Comparisons › ADCT vs KURA
ADC Therapeutics SA vs Kura Oncology: ADCT and KURA compared
ADC Therapeutics SA is the larger company: $21.7M of revenue in its latest quarter (Q3 2026) against $20.9M for Kura Oncology (Q2 2026). Kura Oncology is growing faster (+36% against +32% a year earlier). ADC Therapeutics SA is more profitable, with an operating margin of -66.1% against -349.8%.
Where the money goes: ADCT and KURA
ADC Therapeutics SA (ADCT) · Q3 2026
ADC Therapeutics SA, Q3 2026: revenue $21.7M (+32% year over year), operating margin -66.1%, net loss $25.3M. The chart follows the revenue to costs, profit and cash.
Kura Oncology (KURA) · Q2 2026
Kura Oncology, Q2 2026: revenue $20.9M (+36% year over year), operating margin -349.8%, net loss $68.3M, operating cash flow −$62.5M. The chart follows the revenue to costs, profit and cash.
| ADC Therapeutics SA (ADCT) | Kura Oncology (KURA) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $21.7M | $20.9M |
| Revenue growth, Y/Y | +32% | +36% |
| Operating margin | -66.1% | -349.8% |
| Net earnings | −$25.3M | −$68.3M |
| Net margin | -116.5% | -327.3% |
| Operating cash flow | — | −$62.5M |
Where the revenue comes from
ADC Therapeutics SA
- Product revenues, net: $21.0M (97%)
- License revenues and royalties: $710K (3%)
Kura Oncology
- License and Collaboration Revenue: $11.8M (56%)
- Product: $9.1M (44%)
Questions
Which is bigger, ADC Therapeutics SA or Kura Oncology?
ADC Therapeutics SA is the larger company: $21.7M of revenue in its latest quarter (Q3 2026) against $20.9M for Kura Oncology (Q2 2026).
Is ADC Therapeutics SA or Kura Oncology growing faster?
Kura Oncology is growing faster (+36% against +32% a year earlier).
Which is more profitable, ADC Therapeutics SA or Kura Oncology?
ADC Therapeutics SA is more profitable, with an operating margin of -66.1% against -349.8%.
More: ADC Therapeutics SA earnings · how ADC Therapeutics SA makes money · Kura Oncology earnings · how Kura Oncology makes money
From the companies' latest 10-Q, 10-K or earnings release (8-K filed Nov 9, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.